Joint statement on diabetes treatment

ANZCA has published a joint statement with diabetes groups in Australia and NZ on periprocedural diabetic ketoacidosis and SGLT2i use.

ANZCA has published a joint statment with diabetes groups in Australia and NZ on periprocedural diabetic ketoacidosis and SGLT2i use.

The statement outlines a number of key considerations and suggested management strategies when seeing patients who are taking SGLT2i medication.

Find out more about …

Last updated 09:07 30.06.2020